Genmab实验性卵巢癌药物Rina-S晚期试验达到关键终点，股价大涨
Genmab Soars as Cancer Drug Impresses in a Late-Stage Trial
Genmab表示，其实验性卵巢癌药物Rina-S（rinatabart sesutecan）在晚期试验中使耐铂类卵巢癌患者疾病进展或死亡风险降低71%，并达到主要终点和关键次要终点。消息公布后，Genmab股价升至六年多来的最大涨幅，分析师预期之外的试验结果提振了市场对其研发管线的信心。
Rina-S的晚期试验结果及股价反应，为判断耐铂类卵巢癌药物研发进展和Genmab管线信心提供了具体参照。
October 26, 2026 at 10:01 AM UTC
Takeaways by Bloomberg AI
Genmab A/S shares surged the most in more than six years after its experimental ovarian cancer treatment exceeded analyst expectations in a late-stage trial, boosting confidence in the Danish drugmaker’s pipeline.
The Rina-S drug, or rinatabart sesutecan, cut the risk of disease progression or death by 71% in a group of patients with platinum-resistant ovarian cancer, Genmab said late Friday. The trial met its primary and key secondary endpoints.
来源：Bloomberg Markets · bloomberg.com